Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00524797|
Recruitment Status : Unknown
Verified September 2007 by Ziv Hospital.
Recruitment status was: Recruiting
First Posted : September 5, 2007
Last Update Posted : September 5, 2007
Myelosuppression (bone marrow suppression) is the most important toxic side effect of the majority of chemotherapeutic agents and typically is the dose limiting factor. Death occurring after chemotherapy usually results either from infection related to drug induced leucopenia or from bleeding related to thrombocytopenia. Colony stimulating factors (CSFs) are widely used in the treatment of chemotherapy induced neutropenia. The same Erythropoetines are used in the treatment of chemotherapy induced anemia. Both treatments are expensive and have several side effects.
In our previous stud (1) we found a special kind of honey: Life-Mel Honey to reduce the incidence of chemotherapy induced pancytopenia and improving quality of life.
The aim of the recent planed study is to provide prophylactic and protective treatment against neutropenia reducing the need for secondary CSF administration in patients receiving chemotherapy along with a natural and non expensive honey: Profonycia.
This honey which is expressed in Kibutz Shamir in Upper Galliee seems promising and easy for administration: given 5 gr/day per os for 7 days from the administration of chemotherapy.
|Condition or disease||Intervention/treatment|
|Myelosuppression||Dietary Supplement: Profonycia|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy|
|Study Start Date :||September 2007|
Active Comparator: Main
50 patients will receive Profonycia 5 gr/day PO for 7 days
|Dietary Supplement: Profonycia|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524797
|Contact: Zidan Jamal, Prof||+972 4 6828951|
|Oncology Unit, Ziv MC||Recruiting|
|Safed, Israel, 13110|
|Contact: Zidan Jamal, Prof +972 4 682 8951|
|Principal Investigator: Zidan Jamal, Prof|
|Sub-Investigator: Lika Chetber, MD|
|Sub-Investigator: Amira Avzach|
|Oncology Unit||Not yet recruiting|
|Safed, Israel, 13110|
|Contact: Jamal Zidan, Prof + 972 4 6828951|
|Principal Investigator:||Zidan Jamal, Prof||Ziv MC|